Holzer & Holzer, LLC is investigating whether statements made by Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI) regarding its business and operations complied with federal securities laws. On July 26, 2016, Tokai announced that it was ending a late-stage trial of galeterone, its potential prostate cancer therapy. The Company stated that it did not believe the phase 3 study would meet its primary endpoint. The price of Tokai stock fell dramatically following the announcement.

If you purchased Tokai common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or via toll-free telephone at (888) 508-6832, to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.